Trial Profile
Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Epoetin alfa (Primary) ; Ribavirin (Primary) ; Peginterferon alfa-2b
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 19 Apr 2012 Results have been presented at the International Liver Congress(TM)/47th European Association for the Study of the Liver (EASL) annual meeting, according to a Merck media release.
- 19 Apr 2012 Results will be presented at the International Liver Congress(TM)/47th European Association for the Study of the Liver (EASL) annual meeting, according to a Merck media release.
- 19 Apr 2012 Results published in a Merck media release.